Hanmi Faces Another Licensee UTurn This Time Janssen On ObesityDiabetes Drug

Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic...

More From BioPortfolio on "Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug"